In ‘sur­prise’ move, BioX­cel files for can­cer sub­sidiary to go pub­lic

BioX­cel is fil­ing for its one-year-old can­cer sub­sidiary to go pub­lic af­ter pre­vi­ous­ly say­ing that it was “ex­plor­ing strate­gic op­tions” for the com­pa­ny in its fourth quar­ter re­port.

On Tues­day, BioX­cel an­nounced that its can­cer arm, OnkosX­cel, filed to be­come a pub­lic com­pa­ny, though its tick­er sym­bol, num­ber of shares and price range for the ini­tial pub­lic of­fer­ing were not yet set.

Mizuho an­a­lyst Graig Su­van­nave­jh wrote in a note to in­vestors that the com­pa­ny’s “de­ci­sion to IPO comes, to us, as a sur­prise.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER